Filing Flows

Filing Flows › Alamar Biosciences (ALMR) › Who owns the stock

Who owns Alamar Biosciences (ALMR) stock

82 funds reported Alamar Biosciences (ALMR) shares in their latest 13F filings, worth $479M in all. The largest holder is Samsara BioCapital, LLC ($67.2M). Last quarter 77 funds added to their stakes and 0 cut them.

Largest holders of ALMR (13F)Largest holders of ALMR (13F)Samsara BioCapital, LLC$67.2MT. Rowe Price Investment Manageme…$59.7MARK Investment Management LLC$37.2MAlliancebernstein L.P.$27.2MHhlr Advisors$25.9MBlackRock$24.7MMillennium Management LLC$23.5MFMR LLC$22.5MEmerald Advisers, LLC$17.5MArtisan Partners Limited Partners…$16.6M

Largest holders (13F)

FundSharesValueChangeQuarter
Samsara BioCapital, LLC2,480,310$67.2Mnew2026-06-30
T. Rowe Price Investment Management2,202,597$59.7Mnew2026-06-30
ARK Investment Management LLC1,373,959$37.2Mnew2026-06-30
Alliancebernstein L.P.1,003,077$27.2Mnew2026-06-30
Hhlr Advisors956,462$25.9Mnew2026-06-30
BlackRock911,445$24.7Mnew2026-06-30
Millennium Management LLC865,764$23.5Mnew2026-06-30
FMR LLC829,424$22.5Mnew2026-06-30
Emerald Advisers, LLC647,183$17.5Mnew2026-06-30
Artisan Partners Limited Partnership613,744$16.6Mnew2026-06-30
Deerfield Management Company, L.P. (series C)600,000$16.3Mnew2026-06-30
Vanguard Capital Management LLC463,385$12.6Mnew2026-06-30
Wellington Management Group LLP457,974$12.4Mnew2026-06-30
Emerald Mutual Fund Advisers Trust422,127$11.4Mnew2026-06-30
Ameriprise Financial418,965$11.3Mnew2026-06-30

Alamar Biosciences' latest quarter

Alamar Biosciences, Q3 2026: revenue $33.5M (+68% year over year), operating margin -45.1%, net loss $13.3M, operating cash flow −$14.7M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most ALMR stock?

By the latest 13F filings: Samsara BioCapital, LLC ($67.2M); T. Rowe Price Investment Management ($59.7M); ARK Investment Management LLC ($37.2M); Alliancebernstein L.P. ($27.2M); Hhlr Advisors ($25.9M).

What is the short interest in ALMR?

2,676,396 shares were sold short at the 2026-10-15 settlement, -4.79% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.